Alexion Pharmaceuticals
ALXN
ALXN was delisted on the 20th of July, 2021.
705 hedge funds and large institutions have $22.4B invested in Alexion Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 123 funds opening new positions, 248 increasing their positions, 247 reducing their positions, and 66 closing their positions.
86% more first-time investments, than exits
New positions opened: 123 | Existing positions closed: 66
24% more capital invested
Capital invested by funds: $18B → $22.4B (+$4.37B)
11% more funds holding in top 10
Funds holding in top 10: 19 → 21 (+2)
8% more funds holding
Funds holding: 653 → 705 (+52)
0% more repeat investments, than reductions
Existing positions increased: 248 | Existing positions reduced: 247
19% less call options, than puts
Call options by funds: $305M | Put options by funds: $378M
Top Buyers
| 1 |
LSV Asset Management
Chicago,
Illinois
|
+$281M |
| 2 |
BlackRock
New York
|
+$214M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$119M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
+$106M |
| 5 |
JP Morgan Chase
New York
|
+$92.4M |
Top Sellers
| 1 |
Citadel Advisors
Miami,
Florida
|
-$185M |
| 2 |
Ninety One (UK)
London,
United Kingdom
|
-$144M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$117M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$113M |
| 5 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$95.7M |
ALXN Hedge Fund Activity: Q2 2020 in Review
705 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q2 2020, worth a combined $22.4B — up 24% from $18B a quarter earlier.
Buyers outnumbered sellers: 123 funds opened new ALXN positions and 66 closed out — a net gain of 57 holders — while 248 added to existing stakes and 247 trimmed.
The largest buyer was LSV Asset Management, adding an estimated $281M. The largest seller was Citadel Advisors, cutting an estimated $185M.
- 705 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q2 2020, up from 653 in Q1 2020.
- Funds reported $22.4B of Alexion Pharmaceuticals stock for Q2 2020, up 24% quarter-over-quarter.
- 123 funds opened new Alexion Pharmaceuticals positions in Q2 2020 and 66 closed out, a net change of +57 holders.
- The largest Alexion Pharmaceuticals buyer in Q2 2020 was LSV Asset Management, an estimated $281M added.
- The largest Alexion Pharmaceuticals seller in Q2 2020 was Citadel Advisors, an estimated $185M sold.
Based on aggregated 13F filings for Q2 2020.